Raloxifene Inhibits Estrogen-induced Up-regulation of Telomerase Activity in a Human Breast Cancer Cell Line*

The mechanism by which raloxifene acts in the chemoprevention of breast cancer remains unclear. Because telomerase activity is involved in estrogen-induced carcinogenesis, we examined the effect of raloxifene on estrogen-induced up-regulation of telomerase activity in MCF-7 human breast cancer cell line. Raloxifene inhibited the induction of cell growth and telomerase activity by 17β-estradiol (E2). Raloxifene inhibited the E2-induced expression of the human telomerase catalytic subunit (hTERT), and transient expression assays using luciferase reporter plasmids containing various fragments of the hTERT promoter showed that the estrogen-responsive element appeared to be partially responsible for the action of raloxifene. E2 induced the phosphorylation of Akt, and pretreatment with a phosphatidylinositol 3-kinase (PI3K) inhibitor, LY294002, attenuated the E2-induced increases of the telomerase activity and hTERT promoter activity. Raloxifene inhibited the E2-induced Akt phosphorylation. In addition, raloxifene also inhibited the E2-induced hTERT expression via the PI3K/Akt/NFκB cascade. Moreover, raloxifene also inhibited the E2-induced phosphorylation of hTERT, association of NFκB with hTERT, and nuclear accumulation of hTERT. These results show that raloxifene inhibited the E2-induced up-regulation of telomerase activity not only by transcriptional regulation of hTERT via an estrogen-responsive element-dependent mechanism and the PI3K/Akt/NFκB cascade but also by post-translational regulation via phosphorylation of hTERT and association with NFκB.

[1]  T. Powles,et al.  Continued Breast Cancer Risk Reduction in Postmenopausal Women Treated with Raloxifene: 4-Year Results from the MORE Trial , 2004, Breast Cancer Research and Treatment.

[2]  L. Hartmann,et al.  Selective estrogen-receptor modulators -- mechanisms of action and application to clinical practice. , 2003, The New England journal of medicine.

[3]  J Cuzick,et al.  Overview of the main outcomes in breast-cancer prevention trials , 2003, The Lancet.

[4]  K. Anderson,et al.  Nuclear Factor-κB p65 Mediates Tumor Necrosis Factor α-induced Nuclear Translocation of Telomerase Reverse Transcriptase Protein , 2003 .

[5]  M Baum,et al.  First results from the International Breast Cancer Intervention Study (IBIS-I): a randomised prevention trial , 2002, The Lancet.

[6]  Kazuhiro Takahashi,et al.  Inhibition of Phosphorylation of BAD and Raf-1 by Akt Sensitizes Human Ovarian Cancer Cells to Paclitaxel* , 2002, The Journal of Biological Chemistry.

[7]  B. Monia,et al.  PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells , 2002, Oncogene.

[8]  P. Hartge,et al.  Menopausal hormone replacement therapy and risk of ovarian cancer. , 2002, JAMA.

[9]  P. Dennis,et al.  Constitutive and inducible Akt activity promotes resistance to chemotherapy, trastuzumab, or tamoxifen in breast cancer cells. , 2002, Molecular cancer therapeutics.

[10]  K. Anderson,et al.  Cytokines modulate telomerase activity in a human multiple myeloma cell line. , 2002, Cancer research.

[11]  M. Karin,et al.  Missing Pieces in the NF-κB Puzzle , 2002, Cell.

[12]  O. Stål,et al.  Activation of AKT/PKB in breast cancer predicts a worse outcome among endocrine treated patients , 2002, British Journal of Cancer.

[13]  J. Hayakawa,et al.  Induction of Endothelial Nitric-oxide Synthase Phosphorylation by the Raloxifene Analog LY117018 Is Differentially Mediated by Akt and Extracellular Signal-regulated Protein Kinase in Vascular Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[14]  A. Bilancio,et al.  PI3‐kinase in concert with Src promotes the S‐phase entry of oestradiol‐stimulated MCF‐7 cells , 2001, The EMBO journal.

[15]  P. Nelson,et al.  A novel mechanism for chaperone-mediated telomerase regulation during prostate cancer progression. , 2001, Cancer research.

[16]  N. Taniguchi,et al.  Estrogen Induces the Akt-dependent Activation of Endothelial Nitric-oxide Synthase in Vascular Endothelial Cells* , 2001, The Journal of Biological Chemistry.

[17]  L. Yin,et al.  NF-κB Regulates Transcription of the Mouse Telomerase Catalytic Subunit* , 2000, The Journal of Biological Chemistry.

[18]  Takashi Tsuruo,et al.  Involvement of 14‐3‐3 proteins in nuclear localization of telomerase , 2000, The EMBO journal.

[19]  S. Kyo,et al.  Estrogen activates telomerase. , 1999, Cancer research.

[20]  J. Romashkova,et al.  NF-κB is a target of AKT in anti-apoptotic PDGF signalling , 1999, Nature.

[21]  L. Pfeffer,et al.  NF-κB activation by tumour necrosis factor requires the Akt serine–threonine kinase , 1999, Nature.

[22]  S. Do,et al.  Akt Protein Kinase Enhances Human Telomerase Activity through Phosphorylation of Telomerase Reverse Transcriptase Subunit* , 1999, The Journal of Biological Chemistry.

[23]  S. Kornbluth,et al.  Maintenance of G2 arrest in the Xenopus oocyte: a role for 14‐3‐3‐mediated inhibition of Cdc25 nuclear import , 1999, The EMBO journal.

[24]  G. Morin,et al.  Functional requirement of p23 and Hsp90 in telomerase complexes. , 1999, Genes & development.

[25]  C K Redmond,et al.  Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. , 1999, Journal of the National Cancer Institute.

[26]  T. Powles,et al.  Interim analysis of the incidence of breast cancer in the Royal Marsden Hospital tamoxifen randomised chemoprevention trial , 1998, The Lancet.

[27]  P. Boyle,et al.  Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women , 1998, The Lancet.

[28]  G. Ghosh,et al.  Crystal structure of p50/p65 heterodimer of transcription factor NF-κB bound to DNA , 1998, Nature.

[29]  M. Gerritsen,et al.  Novel Inhibitors of Cytokine-induced IκBα Phosphorylation and Endothelial Cell Adhesion Molecule Expression Show Anti-inflammatory Effects in Vivo* , 1997, The Journal of Biological Chemistry.

[30]  C. Tropé,et al.  Tamoxifen in the Treatment of Recurrent Ovarian Carcinoma , 1997 .

[31]  J. Shay,et al.  A survey of telomerase activity in human cancer. , 1997, European journal of cancer.

[32]  S. Kyo,et al.  Expression of AP1 during cellular differentiation determines human papillomavirus E6/E7 expression in stratified epithelial cells. , 1997, The Journal of general virology.

[33]  E. Barrett-Connor.  Sex differences in coronary heart disease. Why are women so superior? The 1995 Ancel Keys Lecture. , 1997, Circulation.

[34]  David Baltimore,et al.  NF-κB: Ten Years After , 1996, Cell.

[35]  K. Hatch,et al.  Tamoxifen in platinum-refractory ovarian cancer: a Gynecologic Oncology Group Ancillary Report. , 1996, Gynecologic oncology.

[36]  S. Oparil,et al.  Estrogen reduces myointimal proliferation after balloon injury of rat carotid artery. , 1996, Circulation.

[37]  M. Osborne,et al.  The Role of Estrogen in Mammary Carcinogenesis a , 1995, Annals of the New York Academy of Sciences.

[38]  C B Harley,et al.  Telomeres and telomerase in aging and cancer. , 1995, Current opinion in genetics & development.

[39]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[40]  L. Cheng,et al.  Effect of estradiol on accelerated atherosclerosis in rabbit heterotopic aortic allografts. , 1992, The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation.

[41]  J. Manson,et al.  Postmenopausal estrogen therapy and cardiovascular disease. Ten-year follow-up from the nurses' health study. , 1991, The New England journal of medicine.

[42]  E. Blackburn,et al.  A telomeric sequence in the RNA of Tetrahymena telomerase required for telomere repeat synthesis , 1989, Nature.

[43]  T. Clarkson,et al.  Pregnancy‐Associated Inhibition of Coronary Artery Atherosclerosis in Monkeys: Evidence of a Relationship with Endogenous Estrogen , 1987, Arteriosclerosis.

[44]  Carol W. Greider,et al.  Identification of a specific telomere terminal transferase activity in tetrahymena extracts , 1985, Cell.